Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression

Oncogene

Volumn 27, Issue 40, 2008, Pages 5326-5338

  Yang, J ^a   Song, K ^a   Krebs, T L ^a   Jackson, M W ^a   Danielpour, D ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; CDE; CHR; E2F; Promoter regulation; Prostate cancer

Indexed keywords

RETINOBLASTOMA PROTEIN; SMAD PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR E2F4; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; DOWN REGULATION; GENE REPRESSION; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

APOPTOSIS; BLOTTING, WESTERN; E2F4 TRANSCRIPTION FACTOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RESPONSE ELEMENTS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 51649119264     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.165     Document Type: Article

References (44)

1. Altieri DC. (2003a). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
2. Altieri DC. (2003b). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
3. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. (1997). Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
4. Chen CR, Kang Y, Siegel PM, Massague J. (2002). E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110: 19-32.
5. Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. (2001). Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 276: 26614-26621.
6. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ et al. (2002). The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277: 1240-1248.
7. Danielpour D. (2005). Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857.
8. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. (1994). Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54: 3413-3421.
9. Danielpour D, Song K. (2006). Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 17: 59-74.
10. Derynck R, Zhang YE. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
11. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. (2004). Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 24: 2546-2559.
12. Harbour JW, Dean DC. (2000). Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65-E67.
13. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV et al. (1998). Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367.
14. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. (2000). Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 260: 1-12.
15. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D. (1996). Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 56: 5146-5149.
16. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
17. 2. J Cell Sci 118: 1821-1832.
18. Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D et al. (2002). Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 185: 191-199.
19. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. (2004). Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279: 40511-40520.
20. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. (2004). Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171: 1855-1860.
21. Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. (1999). The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 18: 5239-5245.
22. Le Cam L, Polanowska J, Fabbrizio E, Olivier M, Philips A, Ng Eaton E et al. (1999). Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. EMBO J 18: 1878-1890.
23. Liston P, Fong WG, Korneluk RG. (2003). The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568-8580.
24. Liu N, Lucibello FC, Korner K, Wolfraim LA, Zwicker J, Muller R. (1997). CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res 25: 4915-4920.
25. Lucibello FC, Liu N, Zwicker J, Gross C, Muller R. (1997). The differential binding of E2F and CDF repressor complexes contributes to the timing of cell cycle-regulated transcription. Nucleic Acids Res 25: 4921-4925.
26. Massague J, Seoane J, Wotton D. (2005). Smad transcription factors. Genes Dev 19: 2783-2810.
27. Massague J, Wotton D. (2000). Transcriptional control by the TGF-beta/ Smad signaling system. EMBO J 19: 1745-1754.
28. Pennati M, Binda M, Colella G, Zoppe M, Folini M, Vignati S et al. (2004). Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23: 386-394.
29. Roberts AB, Wakefield LM. (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
30. Salvesen GS, Duckett CS. (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
31. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM et al. (2004). Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100: 751-757.
32. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM et al. (2007). Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 67: 6192-6203.
33. Shi Y, Massague J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
34. Song K, Cornelius SC, Danielpour D. (2003a). Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Cancer Res 63: 4358-4367.
35. Song K, Cornelius SC, Reiss M, Danielpour D. (2003b). Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 278: 38342-38351.
36. Song K, Wang H, Krebs TL, Danielpour D. (2006). Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J 25: 58-69.
37. Tang B, De Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP et al. (1999). Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 59: 4834-4842.
38. Taylor WR, Schonthal AH, Galante J, Stark GR. (2001). p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem 276: 1998-2006.
39. Ten Dijke P, Hill CS. (2004). New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29: 265-273.
40. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. (2006). Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 281: 16207-16219.
41. Wang H, Song K, Sponseller TL, Danielpour D. (2005). Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 280: 5154-5162.
42. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M et al. (1992). TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014.
43. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B et al. (1998). Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611-617.
44. Zhang M, Latham DE, Delaney MA, Chakravarti A. (2005). Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482.